Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty

Launched by UNIVERSITY OF MIAMI · Mar 2, 2020

Keywords

ClinConnect Summary

This clinical trial is investigating the best way to use low-dose aspirin to prevent blood clots in patients who have just had total hip or knee replacement surgery. Specifically, the study is comparing whether taking 81 mg of aspirin once a day is just as effective as taking it twice a day. Blood clots can be a serious complication after surgery, so finding the right dosage is important for patient safety.

To participate in this study, you need to be at least 18 years old and planning to have a hip or knee replacement surgery. However, some people may not qualify, including those with certain medical conditions, a high body mass index (BMI), or those who are pregnant. If you join the trial, you'll be assigned to one of the two aspirin groups and will be monitored for how well the treatment works in preventing blood clots. This study is currently looking for volunteers, and it’s a great opportunity to help improve care for future patients undergoing similar surgeries.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • \> 18 years of age
• • Planning to undergo a primary total hip or knee arthroplasty
• Exclusion Criteria:
• * High risk patients for VTE as defined by:
• • History of venous thromboembolism
• • Active malignancy
• • Known pro thrombotic condition
• • BMI \> 40
• • Patients requiring anticoagulation for pre-existing conditions
• • Patients with the contraindication for use of aspirin or nonsteroidal antiinflammatory drugs for reasons such as peptic ulcer disease, intolerance, others.
• • Patients not fluent in the language of the informed consent form
• • Prisoners
• • Pregnancy
• • Reported to have mental illness or belonging to a vulnerable population